Complete Guide to evinacumab Pharmacokinetics
Overview
evinacumab is a Monoclonal Antibody (ANGPTL3 Inhibitor) used in the Cardiovascular / Lipid Disorders therapeutic area. It is indicated for HoFH. Population PK simulator for evinacumab (Evkeeza), an ANGPTL3 inhibitor for homozygous familial hypercholesterolemia (HoFH). Two-compartment model with mixed linear and Michaelis-Menten elimination. Supports IV (15 mg/kg q4w) and SC dosing with allometric scaling.
Mechanism of Action
evinacumab exerts its pharmacological effect by targeting ANGPTL3. As a Monoclonal Antibody (ANGPTL3 Inhibitor), it modulates this target to achieve therapeutic efficacy in HoFH. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This 2-CMT mixed elimination model for evinacumab characterizes the time-course of drug concentrations following IV, SC administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
evinacumab is administered via the IV, SC route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Cardiovascular / Lipid Disorders therapeutic area, for the treatment of HoFH, understanding the pharmacokinetics of evinacumab is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect evinacumab pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive evinacumab PK Simulator
Explore evinacumab pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of evinacumab?
The elimination half-life of evinacumab depends on patient-specific factors. Use our interactive evinacumab PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is evinacumab administered?
evinacumab is administered via the IV, SC route. It is indicated for HoFH. As a Monoclonal Antibody (ANGPTL3 Inhibitor), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of evinacumab?
Key pharmacokinetic parameters for evinacumab include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a 2-CMT mixed elimination model to characterize the pharmacokinetics of evinacumab.
Can I simulate evinacumab dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive evinacumab PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.